Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 9/20 | 0.56 |
| ▸ | BCHE | P06276 | 7/20 | 0.56 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.44 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5487183 | 0.78 | ACHE (0.59) | ACHEBCHECHRM1EPHX2GRIN1 | |
| SCHEMBL7375703 | 0.74 | POLB (0.47) | ACHEBCHECHRM1EPHX2KMT2A | |
| SCHEMBL4271238 | 0.73 | ACHE (1.00) | ACHEBCHECHRM1EPHX2GRIN1 | |
| SCHEMBL5682854 | 0.73 | ACHE (0.94) | ACHEBCHECHRM1EPHX2GRIN1 | |
| SCHEMBL14341607 | 0.71 | ACHE (0.63) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL7380828 | 0.71 | HTT (0.45) | ACHEBCHECHRM1EPHX2KMT2A | |
| SCHEMBL5479586 | 0.70 | ACHE (0.81) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL9654428 | 0.68 | ACHE (0.67) | ACHEBCHECHRM1EPHX2 | |
| SCHEMBL11680018 | 0.68 | SIRT1 (1.00) | SIRT1SMN1; SMN2 | |
| SCHEMBL29958561 | 0.67 | SIRT1 (0.52) | EPHX2SIRT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070299093-A1 | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation | Alma Mater Studiorum-Universitá Di Bologna (IT) | 2007-12-27 | — | — | US | disclosed |
| US-7307083-B2 | Tetrahydro-acridine and dithiolane derivatives | ALMA MATER STUDIORUM-UNIVERSITA'DI BOLOGNA (IT) | 2007-12-11 | — | — | US | disclosed |
| EP-1853594-A2 | ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE, THEIR USE AND METHOD OF PREPARATION | Alma Mater Studiorum -Universita' di Bologna (IT) | 2007-11-14 | — | — | EP | disclosed |
| US-20070219241-A1 | Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation | ALMA MATER STUDIORUM-UNIVERSITA'DI BOLOGNA (IT) | 2007-09-20 | — | — | US | disclosed |
| WO-2006080043-A2 | ORGANIC COMPOUNDS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE, THEIR USE AND METHOD OF PREPARATION | ALMA MATER STUDIORUM- UNIVERSITA' DI BOLOGNA (IT) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070219241-A1 | Organic Compounds Useful For The Treatment Of Alzheimer's Disease, Their Use And Method Of Preparation | OTC, PSEN2, PSEN1 | ACHE 5/4885BCHE 7/4885CHRM1 267/4885 |
| US-20070299093-A1 | Organic Compounds Useful for the Treatment of Alzheimer's Disease, Their Use and Method of Preparation | OTC, PSEN2, PSEN1 | ACHE 5/4885BCHE 7/4885CHRM1 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.